Skip to Main Content
Phase III

Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis

  • Study HIC#:2000025172
  • Last Updated:04/05/2022

Yale is participating in this phase III research study that is testing a new stem cell therapy treatment for perianal fistulas with Crohn’s Disease.

You may qualify if:

  • You are between the ages of 18 to 75
  • Have been diagnosed with Crohn’s Disease for at least 6 months
  • Are not having symptoms of Crohn’s Disease but have perianal fistula(s) that have not responded to treatment
  • Age18 years and older
  • GenderBoth
  • Start Date12/06/2019
  • End Date08/31/2022

Trial Purpose and Description

The purpose of this phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex perianal fistula(s) in patients with Crohn's disease over a period of 24 weeks and a follow-up period up to 52 weeks.

Eligibility Criteria

You may qualify if:

  • You are between the ages of 18 to 75
  • Have been diagnosed with Crohn’s Disease for at least 6 months
  • Are not having symptoms of Crohn’s Disease but have perianal fistula(s) that have not responded to treatment

Principal Investigator

For more information about this study, contact:

Or contact the Help us Discover team on: